IGF2BP1/IMP1 Antibody

About the Target

IGF2BP1/IMP1 is a target of interest in many antibody-based workflows. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), also called IMP1, is an evolutionarily conserved RNA-binding protein involved in post-transcriptional gene regulation through modulation of mRNA stability, localization, and translation. IGF2BP1 contains multiple RNA recognition motifs (RRMs) and K homology (KH) domains, which mediate its selective binding to target mRNAs, often within their 3' untranslated regions, thereby affecting their fate in the cell. Depending on the literature source, IGF2BP1/IMP1 may also be discussed as IGF2BP1/IMP1 and CRDBP.

Reported cellular context includes cell projection, cytoplasm, nucleus, and synapse, which can matter when signal is compared across treatments or changing cell states. Following IGF2BP1/IMP1 across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.

Research Context

IGF2BP1/IMP1 is commonly interpreted in the context of cancer research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cell projection, cytoplasm, and nucleus, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

• apparent redistribution between cell projection, cytoplasm, and nucleus across matched conditions
• changes associated with proliferative state, oncogenic signaling, or treatment response
• co-patterning with orthogonal markers and control conditions that clarify pathway state
• time-matched comparisons so changes reflect biology rather than handling or sampling drift

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for IGF2BP1/IMP1. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in IGF2BP1/IMP1 reflect biology rather than handling. When interpreting IGF2BP1/IMP1, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep IGF2BP1/IMP1 trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.